ReviewReviews in endocrine & metabolic disorders2008
Acromegaly: re-thinking the cancer risk.
Review in Reviews in endocrine & metabolic disorders, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 125 citations in OpenAlex.
- Short-term, supra-physiological rhGH administration induces transient DNA damage in peripheral lymphocytes of healthy women.Journal of endocrinological investigation · 2017Trial
- Acromegaly is associated with an increased incidence of primary malignant tumors: data from a national study in Sweden.The Journal of clinical endocrinology and metabolism · 2026Article
- Clinical and Genetic Spectrum of Large AIP Deletions.Human mutation · 2026Article
- Thromboembolic and cerebrovascular events as initial clues to acromegaly: A clinical case series and review of pathophysiologic links.SAGE open medical case reports · 2026Article
- Nutrition, GH/IGF-1 signaling, and cancer.Endocrine-related cancer · 2024Review
- Disease control of acromegaly does not prevent excess mortality in the long term: results of a nationwide survey in Italy.Journal of endocrinological investigation · 2024Observational
- Pituitary tumors and the risk of other malignancies: is the relationship coincidental or causal?Endocrine oncology (Bristol, England) · 2022Review
- The role of IGF-pathway biomarkers in determining risks, screening, and prognosis in lung cancer.Oncotarget · 2022Review
- Acromegaly and Colorectal Neoplasm: An Update.Frontiers in endocrinology · 2022Review
- An Update on Pituitary Neuroendocrine Tumors Leading to Acromegaly and Gigantism.Journal of clinical medicine · 2021Review
- Insulin-Like Growth Factor Pathway and the Thyroid.Frontiers in endocrinology · 2021Review
- Evaluation of the thyroid characteristics of patients with growth hormone-secreting adenomas.BMC endocrine disorders · 2019Article
- Predictors of colonic pathologies in active acromegaly: single tertiary center experience.Wiener klinische Wochenschrift · 2018Article
- Observational
- Acromegaly discovered during a routine out-patient surgical procedure: a case report.Journal of medical case reports · 2017Article
- Risk of Neoplasia in Pediatric Patients Receiving Growth Hormone Therapy--A Report From the Pediatric Endocrine Society Drug and Therapeutics Committee.The Journal of clinical endocrinology and metabolism · 2015Review
- A male patient with acromegaly and breast cancer: treating acromegaly to control tumor progression.BMC cancer · 2015Article
- Increased thyroid cancer risk in acromegaly.Pituitary · 2014Article
- Evaluation of thyroid diseases and differentiated thyroid cancer in acromegalic patients.Endocrine · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acromegaly is characterized by sustained elevation of circulating growth hormone (GH) and insulin-like growth factor I (IGF-I), and is clearly associated with increased morbidity and overall mortality mainly due to cardiovascular, metabolic, and respiratory diseases. Although cancer-related mortality varies widely amongst retroperspective studies, it appears to be consistently elevated mainly in patients with uncontrolled disease. We review individual tumor types including neoplasms of the colon, breast, prostate, and thyroid where in vitro, animal studies, and studies in non-acromegalic cancer patients have established a role for the GH/IGF-I axis in tumor progression and possibly initiation. We highlight deficiencies in data in acromegalic patients where the evidence is less convincing. Instead, we explore the hypothesis that acromegaly, independent of hormone secretion, is a disease that heralds genetic and/or epigenetic alterations predisposing to cancer risk elsewhere.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.